bluebird bio (NASDAQ:BLUE) Upgraded by JPMorgan Chase & Co. to Neutral Rating

JPMorgan Chase & Co. upgraded shares of bluebird bio (NASDAQ:BLUE) from an underweight rating to a neutral rating in a research note released on Monday, Marketbeat.com reports.

A number of other equities research analysts also recently commented on BLUE. Bank of America downgraded bluebird bio from a “buy” rating to a “neutral” rating and reduced their target price for the company from $60.00 to $10.00 in a research report on Friday, November 15th. Barclays upped their price objective on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 31st. StockNews.com assumed coverage on shares of bluebird bio in a report on Friday, December 20th. They issued a “sell” rating on the stock. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a report on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, bluebird bio presently has an average rating of “Hold” and a consensus target price of $44.14.

bluebird bio Stock Down 0.7 %

BLUE stock opened at $4.05 on Monday. bluebird bio has a 52 week low of $3.56 and a 52 week high of $38.40. The firm has a 50-day simple moving average of $7.73 and a 200-day simple moving average of $9.36. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $39.37 million, a P/E ratio of -0.11 and a beta of 0.68.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Regeneron Pharmaceuticals Inc. acquired a new position in bluebird bio during the 4th quarter valued at approximately $175,000. State Street Corp boosted its position in shares of bluebird bio by 1.1% during the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares in the last quarter. SG Americas Securities LLC grew its position in bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after buying an additional 74,185 shares during the last quarter. Captrust Financial Advisors raised its position in shares of bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares during the period. Finally, Verition Fund Management LLC acquired a new position in shares of bluebird bio in the 3rd quarter valued at $42,000. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.